Insertion of Trial and Permanent Infusion Device in Interventional Cancer Care Services, Antibiotic Prophylaxis (561)

Warning

exp date isn't null, but text field is

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Summary

Single dose, IV prophylaxis ≤ 60 minutes prior to skin incision/ intervention.

MRSA: decolonise prior to procedure as per NHS GGC infection control guidelines.

CPE carriers: If identified as Carbapenamase producing Enterobacterales (CPE) carriers contact microbiology.

Table: Procedure. Recommended Antibiotic, Prolonged Surgery

Procedure Recommended Antibiotic Prolonged Surgery > 4 or > 8 hours
Insertion of Trial Infusion and
Insertion of Permanent Infusion device

400 mg IV Teicoplanin

Give 400 mg teicoplanin by slow intravenous injection over 3-5 minutes.

No repeat dosing of teicoplanin.

Last reviewed: 17 November 2020

Next review: 30 November 2023

Author(s): Ysobel Gourlay

Version: 2

Author Email(s): [email protected]

Approved By: Antimicrobial Utilisation Committee

Document Id: 561